Introduction
The issue of antiepileptic drug (AED) withdrawal in patients with clinical remission of seizures still draws the attention of physicians involved in the management of patients with epilepsy. This issue becomes more intriguing when it refers to children and adolescents. Anticipating outcomes in the natural disease course in these young populations is often an uneasy task.
The numerous AED withdrawal studies published in the last 40 years have relied mainly on heterogeneous study groups. It has become clear that focusing attention on etiologically and electroclinically more homogeneous study groups might facilitate implementation of outcome predictive findings into the clinical management of particular groups of patients.
The Commission on Classification and Terminology of the International League Against Epilepsy (ILAE) in 1989issue of AED withdrawal in patients with CFE. [6] [7] [8] As such, the main idea of the authors was to highlight this aspect of prognosis by analyzing withdrawal outcome in a selected group of pediatric CFE.
Patients and methods

Time and setting
This study was part of a larger observational study of probability of recurrence of seizures upon AED withdrawal in a younger population, which encompassed patients with different etiologies and types of epilepsy. The study was conducted over a nine-year period, from January 2001 through December 2009.
The subjects, children and adolescents with epilepsy undergoing AED withdrawal process, or having been weaned from AED, were identified among consecutive follow-up outpatients from two regional referral university hospitals: Institute for Child and Adolescent Health Care in Novi Sad and Clinic of Neurology and Psychiatry for Children and Youth in Belgrade, Serbia (85 km from each other). These tertiary-level hospitals collect patients referred by pediatricians from primary and secondary health care levels. The subjects were seen, diagnosed, and treated by child neurologists and/or neuropaediatricians/epileptologists in the usual outpatient follow-up intervals of three-six months. The records of these patients were retrospectively screened for the occurrence of a relapse after AED withdrawal in the mentioned period. The final evaluation of the seizure status of suitable patients was conducted on December 31, 2009.
Definitions
The diagnosis of epilepsy was ascertained on clinical and neurophysiological grounds. We defined epilepsy as the occurrence of two or more unprovoked seizures or a single unprovoked seizure with accompanying epileptic discharges on EEG. For etiological determination of epilepsy, we used ILAE criteria. 1 Accordingly, CFE was defined as localization-related epilepsy where no definitive etiological pathology could be established. Patients with mental retardation (either clinically or based on applied neuropsychological tests, i.e. IQ < 70), global developmental delay, and neurological deficits were referred to symptomatic focal epilepsies. Patients whose clinical and EEG features were consistent with benign epilepsy with rolandic spikes, benign epilepsy with occipital spikes, and benign infantile focal epilepsies, were referred to the group of idiopathic focal epilepsies. Seizures were classified as focal (simple/complex) and/or generalized (secondarily generalized).
Inclusion criteria
The main inclusion criteria were: (1) diagnosis of CFE according to ILAE; (2) age at onset of epilepsy of less than 16 years; (3) established clinical remission of at least two years before AED withdrawal; (4) follow-up period of at least two years after withdrawal or until seizure relapse in patients who relapsed.
Withdrawal process
The withdrawal of AED was performed gradually in variable periods, with durations ranging from six to 12 months. When patients were taking two or more AEDs, withdrawal started by reducing one of the AEDs first. Withdrawal of the next AED began when the previous drug had been completely discontinued. The AED withdrawal was cancelled if the seizures recurred during the withdrawal course. Timing of the decision to attempt withdrawal was completely up to the physician.
Diagnostic evaluation and follow-up
EEG in both settings was recorded according to the international 10-20 electrode placement system (21 channels), using Oxford Medilec EEG machines. Video EEG has been available for the last six years, and since then, it has been used as routine monitoring. Combined awake-sleep EEG of 30-45 min duration was the established procedure for the AED withdrawal monitoring. EEG readings were conducted at least once during the withdrawal and every three to six months in the post-withdrawal follow-up period.
EEG interpretations through the course of the disease were evaluated by the authors consensus. The interictal EEG abnormalities included focal and/or generalized epileptiform changes (spikes, sharp waves, and spike/wave complexes). In case of only generalized epileptiform discharges, the diagnosis of focal epilepsies was based, along with asymmetrical appearance of epileptiform discharges, on their ictal clinical focal semiology (if witnessed by physician, derived from patient history or by video record).
For the purpose of the study, we reviewed in particular EEG recordings before, during and after AED withdrawal. According to common practice, normalization of EEG was in favor of starting withdrawal process. The presence of pre-withdrawal focal (but not generalized) abnormalities, along with good seizure control, was not considered an obstacle to enter AED withdrawal process.
Possible influences of EEG location or lateralization of epileptic focal discharges during the clinical course were not analyzed, due to known difficulties in precise topographic diagnosis of CFE, including the fluctuating tendency of interictal EEG abnormalities to diffusion and side shifting. 9 Patients without neuro-imaging findings: computerized tomography (CT) and/or magnetic resonance imaging (MRI), were not considered eligible for the study.
Assessment of recurrence risk
The main outcome endpoint in our study was seizure relapse. To identify outcome predictors, the following variables, derived from the case records, were analyzed: sex; age at seizure onset; types of seizures (focal and/or generalized); history of status epilepticus; EEG findings before, during, and after AED withdrawal; AED treatment (monotherapy versus polytherapy and drugs used in monotherapy); duration of AED therapy; seizure freedom while on AED; age at the start of AED withdrawal; history of febrile seizures; family history of epilepsy; and perinatal history. These variables were entered into the computerized patient database. As the treatment was installed at the very onset of the disease (no later than after the second or third attack), the period before the initiation of treatment was not considered a potential relapse predictor.
Statistical analysis
As the main outcome measure was seizure relapse, time to seizure relapse was analyzed by the Kaplan Meier method to illustrate the likelihood of seizure recurrences. The differences between the frequencies of categorical variables were assessed by x 2 test. The risk for recurrence during the follow-up was investigated by the Cox proportional hazard model (uni/multivariate analyses) 10 to allow for variable length of follow-up. Outcome predictive factors were modeled according to the hazard ratio (HR) followed by the 95% confidence interval (CI). Variables for multivariate analysis were selected from the results of univariate analyses. Statistical significance was accepted at p < 0.05. The SPSS version 16.0 software package (SPSS Inc., Chicago, IL) was used for statistical analysis.
Results
Study cohort/general features
The study cohort of CFE patients was derived from the larger cohort, initially consisting of 148 patients with focal epilepsies who underwent AED discontinuation (38 females, 110 males). Due to being non-responders to follow-up or attending other clinics (16 patients), or due to missing neuroimaging data necessary for the etiological classification (7 patients), 23 patients were dropped from the study. Upon exclusion of those patients, 125 patients entered the study (Fig. 1) . Of the 125 patients in the study, 84 patients (68.3%) were classified as having non-idiopathic (cryptogenic and symptomatic) focal epilepsy. Of those 84 patients, 52 (61.90%) patients were assigned as patients with CFE (34 patients came from the area covered by the Belgrade center and 18 patients from the area covered by Novi Sad center).
In CFE cohort, most of the patients were males 36 (69.2%). The median age at seizure onset was 7.5 years. Fourteen children presented with only partial seizures, and 38 with generalized tonic-clonic seizures. Of the 38 patients with generalized seizures, 14 presented only with immediate generalized seizures, and the others had both focal and generalized (tonic or tonic-clonic) seizures in their histories. Regarding the types of focal seizures, 31 patients presented with complex focal seizures, and seven patients presented with simple focal seizures. There was a history of convulsive status epilepticus in three patients.
In most of the patients -32 (61.3%)-seizure control was established during the first year since the beginning of treatment. In 12 patients, it occurred in the 1-3 year period, in seven patients in the 3-5 year period, and in one patient, in 6 years.
The median age at AED withdrawal was 14 years: eight patients at 6-10 years of age, 26 patients at 10-15 years of age, and 18 patients at 16-20 years of age.
The median duration of seizure-free periods before withdrawal was 4 years. In most of the patients, 48 of the 52 (92.3%), that period lasted more than 2.5 years: in 28 patients, 2.5-4 years; in 12 patients, 4.5-6 years; in seven patients, 7-8 years, and in one patient, 12 years.
The median follow-up since the beginning of AED withdrawal in patients who did not relapse was four years. Twenty-five (75.8%) patients were followed for more than two years: 16 (48.5%) were followed for 3-5 years, six (17.3%) for 6-8 years, one for 9 years, one for 10 years, and one for 13 years.
Regarding somatic co-morbidities, there were two patients with bronchial asthma.
The characteristics of the study group are summarized in Table  1 .
Rate and time of seizure relapse
Until the end of observational period, 19 out of 52 (35.85%) patients with CFE relapsed; of those 19 patients, 13 (72.2%) had focal seizures and six had secondarily generalized seizures.
Most relapses (73.7%) occurred during the first 12 months since the beginning of the AED withdrawal, particularly during the first seven months (57.9%) since the beginning of AED withdrawal. In three of the 19 patients who relapsed, seizures recurred during the withdrawal period. After the first 12 months, as shown at Fig. 2 , the probability of having relapses was markedly decreased. The occurrences of relapses, after 12 months since the withdrawal, were at the following times: 18 months (1), 24 months (1), 36 months (1), and 60 months (1).
Differences relating to the occurrence of relapse
The differences relating to the occurrence of relapses are shown in Table 2 .
Females had more relapses than males; this association was statistically significant.
Regarding the pre-withdrawal EEG recordings, patients with relapses more frequently had abnormal EEGs than those without relapses, and the difference showed statistical significance.
In six out of 41 patients with normal pre-withdrawal EEGs, through the period during (3 patients) and after (3 patients) withdrawal, focal epileptiform abnormalities of variable severity reappeared. Regarding those with pre-withdrawal abnormalities, in two out of 11 patients, EEGs normalized in the follow-up, and remained abnormal in nine patients. Therefore, upon completion of AED withdrawal, there were 12, and, through the further followup to the end of the study there were an additional three, for a total of 15 patients with abnormal EEGs.
With respect to above-mentioned EEG changes during and after withdrawal, patients with relapses more frequently had abnormal EEG in these periods. The difference was statistically significant.
Patients whose median age at AED withdrawal was 14 years or older had a significantly higher rate of relapse. Patients whose median age at seizure onset was 7.5 years or older had a higher rate Although not considered a variable of predictive potential, we compared the groups with and without MRI. In the subgroup of patients who had MRIs (42), the relapse rate was in 15 of 78 (35.71%), while in the group who had CT only (10), the relapses occurred in four (40%) patients (NS).
Cox regression analysis was performed to estimate the magnitude and significance of risks that variables of potentially predictive value have for seizure recurrences during follow-up (Table 3) . According to univariate analysis, significant predictors were: female sex; abnormal EEG before withdrawal; abnormal EEG during and after AED withdrawal; and age at AED withdrawal above 14 years. As independent risk factors for seizure relapse according to the multivariate analysis, three remained: abnormal EEG during and after AED withdrawal, female sex, and age at withdrawal.
Discussion
Study cohort
The proportion of patients with CFE within the total cohort of FE who underwent AED withdrawal, as well as within the nonidiopathic group of FE, corresponds to usual representation of CFE in populations of patients with epilepsies. 4 Definitions applied to cryptogenic epilepsies have varied across studies, thus limiting comparison. We did not include patients with cognitive delay as a Family history of epilepsy was noted in 12 (23.07%) patients: first-grade relatives in three patients, and second-degree relatives in nine. b NS: non-significant. c Regarding the AED treatment before withdrawal, monotherapy was carried out in 41 (78.9%) patients: carbamazepine (CBZ) in 24 patients, valproate (VPA) in nine patients, both CBZ and VPA (as switch on monotherapy) in seven patients, and one patient was on phenobarbital. Ten patients were treated simultaneously by two AEDs: CBZ and VPA in six patients, and four patients were treated by VPA and lamotrigine (LMT). During the clinical course, six patients were treated simultaneously by CBZ and VPA; four patients were treated by VPA and lamotrigine (LMT).
Probability of remaining seizure-free some of the studies, in an effort to make the group free of any possible confounders assuming potential symptomatic etiology. The size of the CFE group may not look impressive, but, along with our inclusion and diagnostic criteria, it does reflect the withdrawal rate in these patients in the period studied.
Relapse rate
In our study, the overall relapse rate after discontinuation of antiepileptic medication was 36.5% after two years of seizure freedom and for the median of four-year follow-up. This rate is consistent with the most commonly reported rate of relapses (30-40%) upon discontinuation of AED for childhood-onset epilepsy. 11, 12 Yet, it is markedly higher than the one reported in the comparable study of Ohta et al. 8 , who reported a rate of 8.9% for a similar follow-up period. Verrotti et al. 6 , within a CFE cohort of seizure-free children with a normal EEG before withdrawal, found the rate of relapse to be 27%, which is closer to the results of our study. Actually, if patients with abnormal pre-withdrawal EEG in our study had been excluded, the relapse rate would have been even closer (29.27%). As proposed by Berg et al. 13 , the relapse risk after withdrawal can be considered in the wider context of a wavelike pattern of seizure remission and relapse course in patients with CFE. Most recurrences occurred in the first year after withdrawal, which is consistent with many previous studies 12, 13 and seems to be the most consistent figure of AED withdrawal studies, regardless of the features of the study groups.
Predictive factors for relapse
From a clinical point of view, the essential question is: are there predictive variables for seizure relapse in children with CFE who are candidates for AED withdrawal? According to the results of our study, three variables appeared to be significantly associated with withdrawal outcome.
a) The significantly higher risk for relapse in girls after AED withdrawal might be a reflection of the male predominance over females in the study cohort of CFE. It also was noted in the total cohort of FE patients from whom this CFE cohort was derived. Hence, it might be a possible consequence of selection bias. Supposed referral bias related to males more commonly being referred to epilepsy clinics than females has not been recognized. This finding also may reflect a lower rate of withdrawal in female patients, due to either more severe focal epilepsies or more reluctance to enter the withdrawal process. However, some other studies with mixed epilepsy cohorts 14, 16 also found this association. In two studies, this trend was noticed in females with idiopathic epilepsies. 15, 17 b) Age of AED withdrawal of 14 years or older as a significant risk factor for relapse is in accordance with the findings of the study of Ohta et al. 8 In that study, this age cut-off at 15 years was correlated to the older age of onset of epilepsy as a significant predictor for seizure relapse. In our study, the age at onset was found to be near significant level, which, in a way, correlates with the findings of the mentioned and some other studies. 15 Some other studies with heterogeneous cohorts, did not confirm this association. 18, 19 c) Regarding the very controversial issue about whether or not the EEG findings before withdrawal influence the outcome, reported results vary widely. 11, 12, 17 Our findings support the view of predictive value of pre-withdrawal EEG in selecting patients for AED withdrawal, according to univariate, but not multivariate analysis. It is in accordance with some studies, 19, 20 but not with others. 12, 16 A significant relationship was also found between abnormal EEG during and after AED withdrawal and prognosis. This finding supports rare studies that considered EEG during and/or after withdrawal. Verrotti et al. 7 pointed to the reappearance of EEG abnormalities during AED withdrawal as a risk factor for relapse in patients with CFE. Olmeza et al. and Todt et al. 16, 18 found postwithdrawal EEG to be a risk factor for relapse in heterogeneous cohorts of children with epilepsy. This finding was not supported by some studies, 21 which have found that remaining discharges after withdrawal did not predict the occurrence of a relapse. Some of the other investigated variables, although not significantly related to relapse rate, deserve attention. Seizurefree period of median four years before withdrawal did not influence the relapse risk. This finding correlates with the study of Ohta et al. 8 , although the seizure-free cut-off period was six years.
Verrotti et al. 6 suggested safe AED discontinuation in children with CFE who were seizure-free for only one year. This could not be confirmed by our study. Some studies 18, 19 have reported seizurefree periods shorter than four years as a seizure relapse risk factor in children.
Having secondarily generalized seizures, as well as epileptic status, through the course of the disease, did not influence the relapse risk, which correlates to the finding of Ohta et al. 8 Contrary to the findings in that study, patients treated by polytherapy vs. monotherapy were not under significantly higher risk for relapse rate. We could not confirm significant effects of specific AED in monotherapy on seizure relapses after AED withdrawal.
Limitations of the study
Some additional hidden confounders might influence our data, apart from those already discussed earlier. First, referral pattern can be a source of selection bias. Although the setting of the study assumes more patients whose epilepsy could not be controlled easily, common referral pattern does not include only the difficultto-treat cases. Hence, we believe the patients reasonably fairly reflect the wider population of children with CFE.
Second, regarding our diagnostic concerns to exclude symptomatic epilepsies, MR findings in most of the patients supported our classification. Patients lacking MR could only be verified as non-lesional by CT brain studies. We are aware of limited CT sensitivity and possibilities that epilepsies considered cryptogenic can have some unrecognized subtle cortical dysplasia. 22 We also are aware that exclusion of thus-far recognized idiopathic focal epilepsies leaves space for some other, to date not recognized focal genetic epilepsy types.
